Ophthalmology

InSite Vision and QLT Amend Merger Agreement

ALAMEDA, Calif.—InSite Vision Inc. (OTCBB: INSV) announced on Aug. 28 that InSite and QLT Inc. (NASDAQ: QLTI) (TSX: QLT) entered into a revised merger agreement under which QLT will acquire InSite Vision. InSite Vision specializes in ophthalmologic products that treat ocular infection and inflammation, glaucoma, and retinal diseases. Under the terms of the revised merger agreement, a wholly owned subsidiary of QLT will be merged with and into InSite Vision. At the time of the merger, each InSite Vision share will be exchanged for the following: .078 QLT shares, if the average trading price of QLT shares for the 15-trading…


Allergan to Acquire Glaucoma Treatment Company AqueSys

DUBLIN and ALISO VIEJO, Calif.—Allergan (NYSE: AGN), a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure associated with glaucoma, announced yesterday that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction. Under the terms of the agreement, Allergan will acquire AqueSys for a $300 million upfront payment and regulatory approval and commercialization milestone payments related to AqueSys’ lead development programs, including XEN45. “The acquisition of AqueSys and its XEN45 program builds on Allergan’s deep and long-standing commitment to…